Review





Similar Products

bgp 15  (MedChemExpress)
93
MedChemExpress bgp 15
Bgp 15, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bgp 15/product/MedChemExpress
Average 93 stars, based on 1 article reviews
bgp 15 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
mitochondrially-targeted therapeutics bgp-15  (MitoQ Ltd)
90
MitoQ Ltd mitochondrially-targeted therapeutics bgp-15
Mitochondrially Targeted Therapeutics Bgp 15, supplied by MitoQ Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mitochondrially-targeted therapeutics bgp-15/product/MitoQ Ltd
Average 90 stars, based on 1 article reviews
mitochondrially-targeted therapeutics bgp-15 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
bgp-15  (Guiyang Xintian Pharmaceutical Co Ltd)
90
Guiyang Xintian Pharmaceutical Co Ltd bgp-15
Bgp 15, supplied by Guiyang Xintian Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bgp-15/product/Guiyang Xintian Pharmaceutical Co Ltd
Average 90 stars, based on 1 article reviews
bgp-15 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
bgp-15  (MitoQ Ltd)
90
MitoQ Ltd bgp-15
Bgp 15, supplied by MitoQ Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bgp-15/product/MitoQ Ltd
Average 90 stars, based on 1 article reviews
bgp-15 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
dmso  (Selleck Chemicals)
93
Selleck Chemicals dmso
Figure 5. OPA1 overexpression or activation improved Aβ clearance of microglia and synaptic plasticity (A) Representative images showing the Aβ (red) deposition in the hippocampus of APP/PS1 and APP/PS1-OPA1-OE mice. (B-C) Aβ plaque counts and areas in hippocampus were low in APP/PS1-OPA1-OE mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 4.621 p=0.0099 in (B), t(4) = 4.376 p=0.0119 in (C). (D) Representative images showing the Aβ (green) deposition in the hippocampus of APP/PS1 <t>and</t> <t>BGP-15‐treated</t> APP/PS1 mice. (E-F) Aβ plaque counts and areas in hippocampus were low in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice treated with <t>DMSO.</t> n = 3 for each group. t(4) = 4.330 p=0.0123 in (E), t(4) = 4.167, p=0.0141 in (F). (G) Representative pictures showing colocalization of Aβ (magenta) with IBA-1 (red) and CD68 (green) in the hippocampus of WT, APP/PS1 and APP/PS1-OPA1-OE mice. (H) The number of microglia surrounding Aβ was higher in APP/PS1- OPA1-OE mice compared with APP/PS1 mice. n = 4 for each group. p=0.0286 (I)Representative pictures showing colocalization of Aβ (green) with IBA-1 (red) and CD68 (magenta) in the hippocampus of WT, APP/PS1 and BGP-15‐treated APP/PS1 mice. (J) The number of microglia surrounding Aβ was higher in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 5.483, p=0.0054 (K) The input–output response increased in APP/PS1-OPA1-OE mice (n=3 slices/mouse, N=3 mice/group) compared with APP/PS1 mice (n=3 slices/mouse, N=3 mice/group). F(2,22)=2.035, APP/PS1 versus WT group: p ＜ 0.0001, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.0399. (L and M) The slope of the evoked fEPSP increased in APP/PS1- OPA1-OE mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p=0.0262, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.416. (N) The input–output response increased in BGP-15‐treated APP/PS1 mice (n=2-4 slices/mouse, N=3 mice/group) compared with APP/PS1 mice treated with DMSO (n=2-4 slices/mouse, N=3 mice/group). F(2,20)=4.289, APP/PS1 versus WT group: p =0.0260, APP/PS1 versus APP/PS1+BGP15 group: p＜0.0001. (O and P) The slope of the evoked fEPSP increased in BGP-15‐treated APP/PS1 mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice treated with DMSO during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p =0.0103, APP/PS1 versus APP/PS1+BGP15 group: p=0.0063. Unpaired two-tailed test for (B), (C), (E), (F)and(J). Mann-Whitney U test for (H), Two-way ANOVA followed by Tukey’s post hoc test for (K) and (N). Kruskal-Wallis followed by Dunn's post-hoc test for (M)and (P). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Dmso, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dmso/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
dmso - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
bgp 15  (Selleck Chemicals)
93
Selleck Chemicals bgp 15
Figure 5. OPA1 overexpression or activation improved Aβ clearance of microglia and synaptic plasticity (A) Representative images showing the Aβ (red) deposition in the hippocampus of APP/PS1 and APP/PS1-OPA1-OE mice. (B-C) Aβ plaque counts and areas in hippocampus were low in APP/PS1-OPA1-OE mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 4.621 p=0.0099 in (B), t(4) = 4.376 p=0.0119 in (C). (D) Representative images showing the Aβ (green) deposition in the hippocampus of APP/PS1 <t>and</t> <t>BGP-15‐treated</t> APP/PS1 mice. (E-F) Aβ plaque counts and areas in hippocampus were low in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice treated with <t>DMSO.</t> n = 3 for each group. t(4) = 4.330 p=0.0123 in (E), t(4) = 4.167, p=0.0141 in (F). (G) Representative pictures showing colocalization of Aβ (magenta) with IBA-1 (red) and CD68 (green) in the hippocampus of WT, APP/PS1 and APP/PS1-OPA1-OE mice. (H) The number of microglia surrounding Aβ was higher in APP/PS1- OPA1-OE mice compared with APP/PS1 mice. n = 4 for each group. p=0.0286 (I)Representative pictures showing colocalization of Aβ (green) with IBA-1 (red) and CD68 (magenta) in the hippocampus of WT, APP/PS1 and BGP-15‐treated APP/PS1 mice. (J) The number of microglia surrounding Aβ was higher in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 5.483, p=0.0054 (K) The input–output response increased in APP/PS1-OPA1-OE mice (n=3 slices/mouse, N=3 mice/group) compared with APP/PS1 mice (n=3 slices/mouse, N=3 mice/group). F(2,22)=2.035, APP/PS1 versus WT group: p ＜ 0.0001, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.0399. (L and M) The slope of the evoked fEPSP increased in APP/PS1- OPA1-OE mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p=0.0262, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.416. (N) The input–output response increased in BGP-15‐treated APP/PS1 mice (n=2-4 slices/mouse, N=3 mice/group) compared with APP/PS1 mice treated with DMSO (n=2-4 slices/mouse, N=3 mice/group). F(2,20)=4.289, APP/PS1 versus WT group: p =0.0260, APP/PS1 versus APP/PS1+BGP15 group: p＜0.0001. (O and P) The slope of the evoked fEPSP increased in BGP-15‐treated APP/PS1 mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice treated with DMSO during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p =0.0103, APP/PS1 versus APP/PS1+BGP15 group: p=0.0063. Unpaired two-tailed test for (B), (C), (E), (F)and(J). Mann-Whitney U test for (H), Two-way ANOVA followed by Tukey’s post hoc test for (K) and (N). Kruskal-Wallis followed by Dunn's post-hoc test for (M)and (P). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Bgp 15, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bgp 15/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
bgp 15 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
bgp-15  (N-Gene Research Laboratories)
90
N-Gene Research Laboratories bgp-15
Figure 5. OPA1 overexpression or activation improved Aβ clearance of microglia and synaptic plasticity (A) Representative images showing the Aβ (red) deposition in the hippocampus of APP/PS1 and APP/PS1-OPA1-OE mice. (B-C) Aβ plaque counts and areas in hippocampus were low in APP/PS1-OPA1-OE mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 4.621 p=0.0099 in (B), t(4) = 4.376 p=0.0119 in (C). (D) Representative images showing the Aβ (green) deposition in the hippocampus of APP/PS1 <t>and</t> <t>BGP-15‐treated</t> APP/PS1 mice. (E-F) Aβ plaque counts and areas in hippocampus were low in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice treated with <t>DMSO.</t> n = 3 for each group. t(4) = 4.330 p=0.0123 in (E), t(4) = 4.167, p=0.0141 in (F). (G) Representative pictures showing colocalization of Aβ (magenta) with IBA-1 (red) and CD68 (green) in the hippocampus of WT, APP/PS1 and APP/PS1-OPA1-OE mice. (H) The number of microglia surrounding Aβ was higher in APP/PS1- OPA1-OE mice compared with APP/PS1 mice. n = 4 for each group. p=0.0286 (I)Representative pictures showing colocalization of Aβ (green) with IBA-1 (red) and CD68 (magenta) in the hippocampus of WT, APP/PS1 and BGP-15‐treated APP/PS1 mice. (J) The number of microglia surrounding Aβ was higher in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 5.483, p=0.0054 (K) The input–output response increased in APP/PS1-OPA1-OE mice (n=3 slices/mouse, N=3 mice/group) compared with APP/PS1 mice (n=3 slices/mouse, N=3 mice/group). F(2,22)=2.035, APP/PS1 versus WT group: p ＜ 0.0001, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.0399. (L and M) The slope of the evoked fEPSP increased in APP/PS1- OPA1-OE mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p=0.0262, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.416. (N) The input–output response increased in BGP-15‐treated APP/PS1 mice (n=2-4 slices/mouse, N=3 mice/group) compared with APP/PS1 mice treated with DMSO (n=2-4 slices/mouse, N=3 mice/group). F(2,20)=4.289, APP/PS1 versus WT group: p =0.0260, APP/PS1 versus APP/PS1+BGP15 group: p＜0.0001. (O and P) The slope of the evoked fEPSP increased in BGP-15‐treated APP/PS1 mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice treated with DMSO during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p =0.0103, APP/PS1 versus APP/PS1+BGP15 group: p=0.0063. Unpaired two-tailed test for (B), (C), (E), (F)and(J). Mann-Whitney U test for (H), Two-way ANOVA followed by Tukey’s post hoc test for (K) and (N). Kruskal-Wallis followed by Dunn's post-hoc test for (M)and (P). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Bgp 15, supplied by N-Gene Research Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bgp-15/product/N-Gene Research Laboratories
Average 90 stars, based on 1 article reviews
bgp-15 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
bgp 15 compound bgp 15  (Selleck Chemicals)
96
Selleck Chemicals bgp 15 compound bgp 15
Figure 5. OPA1 overexpression or activation improved Aβ clearance of microglia and synaptic plasticity (A) Representative images showing the Aβ (red) deposition in the hippocampus of APP/PS1 and APP/PS1-OPA1-OE mice. (B-C) Aβ plaque counts and areas in hippocampus were low in APP/PS1-OPA1-OE mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 4.621 p=0.0099 in (B), t(4) = 4.376 p=0.0119 in (C). (D) Representative images showing the Aβ (green) deposition in the hippocampus of APP/PS1 <t>and</t> <t>BGP-15‐treated</t> APP/PS1 mice. (E-F) Aβ plaque counts and areas in hippocampus were low in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice treated with <t>DMSO.</t> n = 3 for each group. t(4) = 4.330 p=0.0123 in (E), t(4) = 4.167, p=0.0141 in (F). (G) Representative pictures showing colocalization of Aβ (magenta) with IBA-1 (red) and CD68 (green) in the hippocampus of WT, APP/PS1 and APP/PS1-OPA1-OE mice. (H) The number of microglia surrounding Aβ was higher in APP/PS1- OPA1-OE mice compared with APP/PS1 mice. n = 4 for each group. p=0.0286 (I)Representative pictures showing colocalization of Aβ (green) with IBA-1 (red) and CD68 (magenta) in the hippocampus of WT, APP/PS1 and BGP-15‐treated APP/PS1 mice. (J) The number of microglia surrounding Aβ was higher in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 5.483, p=0.0054 (K) The input–output response increased in APP/PS1-OPA1-OE mice (n=3 slices/mouse, N=3 mice/group) compared with APP/PS1 mice (n=3 slices/mouse, N=3 mice/group). F(2,22)=2.035, APP/PS1 versus WT group: p ＜ 0.0001, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.0399. (L and M) The slope of the evoked fEPSP increased in APP/PS1- OPA1-OE mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p=0.0262, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.416. (N) The input–output response increased in BGP-15‐treated APP/PS1 mice (n=2-4 slices/mouse, N=3 mice/group) compared with APP/PS1 mice treated with DMSO (n=2-4 slices/mouse, N=3 mice/group). F(2,20)=4.289, APP/PS1 versus WT group: p =0.0260, APP/PS1 versus APP/PS1+BGP15 group: p＜0.0001. (O and P) The slope of the evoked fEPSP increased in BGP-15‐treated APP/PS1 mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice treated with DMSO during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p =0.0103, APP/PS1 versus APP/PS1+BGP15 group: p=0.0063. Unpaired two-tailed test for (B), (C), (E), (F)and(J). Mann-Whitney U test for (H), Two-way ANOVA followed by Tukey’s post hoc test for (K) and (N). Kruskal-Wallis followed by Dunn's post-hoc test for (M)and (P). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Bgp 15 Compound Bgp 15, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bgp 15 compound bgp 15/product/Selleck Chemicals
Average 96 stars, based on 1 article reviews
bgp 15 compound bgp 15 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


Figure 5. OPA1 overexpression or activation improved Aβ clearance of microglia and synaptic plasticity (A) Representative images showing the Aβ (red) deposition in the hippocampus of APP/PS1 and APP/PS1-OPA1-OE mice. (B-C) Aβ plaque counts and areas in hippocampus were low in APP/PS1-OPA1-OE mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 4.621 p=0.0099 in (B), t(4) = 4.376 p=0.0119 in (C). (D) Representative images showing the Aβ (green) deposition in the hippocampus of APP/PS1 and BGP-15‐treated APP/PS1 mice. (E-F) Aβ plaque counts and areas in hippocampus were low in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice treated with DMSO. n = 3 for each group. t(4) = 4.330 p=0.0123 in (E), t(4) = 4.167, p=0.0141 in (F). (G) Representative pictures showing colocalization of Aβ (magenta) with IBA-1 (red) and CD68 (green) in the hippocampus of WT, APP/PS1 and APP/PS1-OPA1-OE mice. (H) The number of microglia surrounding Aβ was higher in APP/PS1- OPA1-OE mice compared with APP/PS1 mice. n = 4 for each group. p=0.0286 (I)Representative pictures showing colocalization of Aβ (green) with IBA-1 (red) and CD68 (magenta) in the hippocampus of WT, APP/PS1 and BGP-15‐treated APP/PS1 mice. (J) The number of microglia surrounding Aβ was higher in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 5.483, p=0.0054 (K) The input–output response increased in APP/PS1-OPA1-OE mice (n=3 slices/mouse, N=3 mice/group) compared with APP/PS1 mice (n=3 slices/mouse, N=3 mice/group). F(2,22)=2.035, APP/PS1 versus WT group: p ＜ 0.0001, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.0399. (L and M) The slope of the evoked fEPSP increased in APP/PS1- OPA1-OE mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p=0.0262, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.416. (N) The input–output response increased in BGP-15‐treated APP/PS1 mice (n=2-4 slices/mouse, N=3 mice/group) compared with APP/PS1 mice treated with DMSO (n=2-4 slices/mouse, N=3 mice/group). F(2,20)=4.289, APP/PS1 versus WT group: p =0.0260, APP/PS1 versus APP/PS1+BGP15 group: p＜0.0001. (O and P) The slope of the evoked fEPSP increased in BGP-15‐treated APP/PS1 mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice treated with DMSO during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p =0.0103, APP/PS1 versus APP/PS1+BGP15 group: p=0.0063. Unpaired two-tailed test for (B), (C), (E), (F)and(J). Mann-Whitney U test for (H), Two-way ANOVA followed by Tukey’s post hoc test for (K) and (N). Kruskal-Wallis followed by Dunn's post-hoc test for (M)and (P). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Journal: aging and disease

Article Title: OPA1 Enhances Microglial Amyloid-β Clearance and Alleviates Cognitive Impairments in an Alzheimer’s Disease Model

doi: 10.14336/ad.2025.0082

Figure Lengend Snippet: Figure 5. OPA1 overexpression or activation improved Aβ clearance of microglia and synaptic plasticity (A) Representative images showing the Aβ (red) deposition in the hippocampus of APP/PS1 and APP/PS1-OPA1-OE mice. (B-C) Aβ plaque counts and areas in hippocampus were low in APP/PS1-OPA1-OE mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 4.621 p=0.0099 in (B), t(4) = 4.376 p=0.0119 in (C). (D) Representative images showing the Aβ (green) deposition in the hippocampus of APP/PS1 and BGP-15‐treated APP/PS1 mice. (E-F) Aβ plaque counts and areas in hippocampus were low in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice treated with DMSO. n = 3 for each group. t(4) = 4.330 p=0.0123 in (E), t(4) = 4.167, p=0.0141 in (F). (G) Representative pictures showing colocalization of Aβ (magenta) with IBA-1 (red) and CD68 (green) in the hippocampus of WT, APP/PS1 and APP/PS1-OPA1-OE mice. (H) The number of microglia surrounding Aβ was higher in APP/PS1- OPA1-OE mice compared with APP/PS1 mice. n = 4 for each group. p=0.0286 (I)Representative pictures showing colocalization of Aβ (green) with IBA-1 (red) and CD68 (magenta) in the hippocampus of WT, APP/PS1 and BGP-15‐treated APP/PS1 mice. (J) The number of microglia surrounding Aβ was higher in BGP-15‐treated APP/PS1 mice compared with APP/PS1 mice. n = 3 for each group. t(4) = 5.483, p=0.0054 (K) The input–output response increased in APP/PS1-OPA1-OE mice (n=3 slices/mouse, N=3 mice/group) compared with APP/PS1 mice (n=3 slices/mouse, N=3 mice/group). F(2,22)=2.035, APP/PS1 versus WT group: p ＜ 0.0001, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.0399. (L and M) The slope of the evoked fEPSP increased in APP/PS1- OPA1-OE mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p=0.0262, APP/PS1 versus APP/PS1-OPA1-OE group: p=0.416. (N) The input–output response increased in BGP-15‐treated APP/PS1 mice (n=2-4 slices/mouse, N=3 mice/group) compared with APP/PS1 mice treated with DMSO (n=2-4 slices/mouse, N=3 mice/group). F(2,20)=4.289, APP/PS1 versus WT group: p =0.0260, APP/PS1 versus APP/PS1+BGP15 group: p＜0.0001. (O and P) The slope of the evoked fEPSP increased in BGP-15‐treated APP/PS1 mice (n=3slices/mouse, N=3mice/group) compared with APP/PS1 mice treated with DMSO during LTP induction (n=3slices/mouse, N=3mice/group). APP/PS1 versus WT group: p =0.0103, APP/PS1 versus APP/PS1+BGP15 group: p=0.0063. Unpaired two-tailed test for (B), (C), (E), (F)and(J). Mann-Whitney U test for (H), Two-way ANOVA followed by Tukey’s post hoc test for (K) and (N). Kruskal-Wallis followed by Dunn's post-hoc test for (M)and (P). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Article Snippet: Mice were treated daily with 20mg/kg BGP-15 dissolved in 10% dimethyl sulfoxide (DMSO) or vehicle 10% DMSO (S8370, Selleck, Shanghai, China) for 15 censecutive days by oral gavage.

Techniques: Over Expression, Activation Assay, Two Tailed Test, MANN-WHITNEY